Journal
JOURNAL OF CONTROLLED RELEASE
Volume 170, Issue 2, Pages 268-278Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2013.05.036
Keywords
Porous silicon; Nanoparticles; Co-delivery; PYY3-36; Indomethacin; Drug release and permeation
Funding
- Academy of Finland [252215, 256394]
- European Research Council under the European Union [310892]
- University of Eastern Finland (NAMBER)
- Finnish Cultural Foundation
- Academy of Finland (AKA) [256394, 256394] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Nanoparticulate drug delivery systems offer remarkable opportunities for clinical treatment. However, there are several challenges when they are employed to deliver multiple cargos/payloads, particularly concerning the synchronous delivery of small molecular weight drugs and relatively larger peptides. Since porous silicon (PSi) nanoparticles (NPs) can easily contain high payloads of drugs with various properties, we evaluated their carrier potential in multi-drug delivery for co-loading of the hydrophobic drug indomethacin and the hydrophilic human peptide YY3-36 (PYY3-36). Sequential loading of these two drugs into the PSi NPs enhanced the drug release rate of each drug and also their amount permeated across Caco-2 and Caco-2/HT29 cell monolayers. Regardless of the loading approach used, dual or single, the drug permeation profiles were in good correlation with their drug release behaviour. Furthermore, the permeation studies indicated the critical role of the mucus intestinal layer and the paracellular resistance in the permeation of the therapeutic compounds across the intestinal wall. Loading with PYY3-36 also greatly improved the cytocompatibility of the PSi NPs. Conformational analysis indicated that the PYY3-36 could still display biological activity after release from the PSi NPs and permeation across the intestinal cell monolayers. These results are the first demonstration of the promising potential of PSi NPs for simultaneous multi-drug delivery of both hydrophobic and hydrophilic compounds. (C) 2013 Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available